SCHEMBL4639664

SCHEMBL4639664

CN(C)S(=O)(=O)c1ccc(N)cc1Cl

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.61
CYP3A4 P08684 4/20 0.47
TSHR P16473 4/20 0.47
THRB P10828 1/20 0.47
HPGD P15428 1/20 0.47
ALOX15 P16050 1/20 0.47
CASP1 P29466 1/20 0.47
RECQL P46063 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
HSD11B1 P28845 1/20 0.44
GSTO1 P78417 6/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
GLA P06280 1/20 0.42
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8936354 0.85 ALDH1A1 (0.61) ALDH1A1CYP3A4TSHRTHRBHPGD
SCHEMBL4639725 0.79 L3MBTL1 (0.63) ALDH1A1CYP3A4TSHRALOX15CASP1
SCHEMBL282188 0.79 L3MBTL1 (0.62) ALDH1A1CYP3A4TSHRTHRBHPGD
SCHEMBL30431062 0.79 L3MBTL1 (0.62) ALDH1A1CYP3A4TSHRTHRBHPGD
SCHEMBL1300150 0.78 CYP3A4 (0.55) ALDH1A1CYP3A4TSHRTHRBHPGD
SCHEMBL4638477 0.78 ALDH1A1 (0.43) ALDH1A1CYP3A4ALOX15CYP2C9CYP2C19
SCHEMBL20489103 0.78 ALDH1A1 (0.51) ALDH1A1TSHRHSD11B1GSTO1CA1
SCHEMBL31195184 0.78 ALDH1A1 (0.43) ALDH1A1CYP3A4ALOX15GSTO1L3MBTL1
SCHEMBL20488864 0.78 ALDH1A1 (0.51) ALDH1A1TSHRHSD17B10GSTO1GLA
SCHEMBL13212960 0.78 CASP1 (0.44) ALDH1A1CYP3A4TSHRTHRBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773768-A4 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2008-08-06 EP claimed
EP-1773768-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2007-04-18 EP claimed
WO-2006012642-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2006-02-02 WO claimed
EP-4719413-A1 INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF Animol Discovery, Inc. (US) 2026-04-08 EP disclosed
US-20260092070-A1 INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF ANIMOL DISCOVERY INC (US) 2026-04-02 US disclosed
WO-2024246837-A1 INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF ANIMOL DISCOVERY, INC. (US) 2024-12-05 WO disclosed
EP-1773768-B1 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2018-08-22 EP disclosed
EP-1844020-B1 HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS EXELIXIS INC (US) 2017-09-06 EP disclosed
US-8367667-B2 Pyrrole derivatives as pharmaceutical agents EXELIXIS, INC. (US) 2013-02-05 US disclosed
US-20110301128-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2011-12-08 US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed
EP-1773768-A4 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2008-08-06 EP disclosed
EP-1844020-A1 HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS Exelixis, Inc. (US) 2007-10-17 EP disclosed
EP-1773768-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2007-04-18 EP disclosed
WO-2006076202-A1 HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTORS LIGANDS EXELIXIS, INC. (US) 2006-07-20 WO disclosed
WO-2006012642-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301128-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 ALDH1A1 2251/4885CYP3A4 2500/4885TSHR 144/4885
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 ALDH1A1 2251/4885CYP3A4 2500/4885TSHR 144/4885
US-20260092070-A1 INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF JAK1, JAK3, JAK2 ALDH1A1 1691/4885CYP3A4 1365/4885TSHR 2190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.